Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

NRSN

NRSN News

Newswire

07:33

NeuroSense Therapeutics resumes PrimeC ALS drug development in Canada.

16:56

NeuroSense shares surge 10.38% after-hours after FDA clears pivotal Phase 3 ALS trial for PrimeC.

11:02

NeuroSense: D. Boral Capital Maintains Buy Rating, Raises PT to $14

10:22

NeuroSense shares surge 10.90% intraday after FDA clears pivotal Phase 3 ALS trial for PrimeC.

10:01

NeuroSense Initiates Pivotal Phase 3 Trial for PrimeC in ALS with FDA Clearance

View More

About NRSN

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More